101 unsupervised dosing, 24, 32, 61 storage, 59 urine drug screening, 36, 160 tetanus, 52 'dipstick' methods, 36 therapeutic communities, 73 directly observed, 37 therapeutic relationship, 30, 155 limitations, 36, 46, 205 tolerance, 15, 21, 24, 77, 98, 99, 104, uses, 10, 36 105, 117, 149, 153, 189, 190 vaccination, 52, 147 treatment goals, 9, 64 withdrawal, 32 treatment planning, 12, 155, 157 assessment, 18, 191 chronic pain, 15, 151 precipitated by antagonists, 46, 47, clinical review, 47 115, 116, 201 coordination, 12 precipitated by buprenorphine, 21, duration, 67 25, 27, 29, 34, 79, 99, 103 patient perspective, 12, 66, 92 protracted, 84 review, 14, 36, 42, 159 signs and symptoms, 83, 88, 111, selection of treatment approach, 134, 203 12, 45, 66, 91, 96, 114, 118, 130, 132, 138
101 storage, 59 tetanus, 52 therapeutic communities, 73 therapeutic relationship, 30, 155 tolerance, 15, 21, 24, 77, 98, 99, 104, 105, 117, 149, 153, 189, 190 treatment goals, 9, 64 treatment planning, 12, 155, 157 chronic pain, 15, 151 clinical review, 47 coordination, 12 duration, 67 patient perspective, 12, 66, 92 review, 14, 36, 42, 159 selection of treatment approach, 12, 45, 66, 91, 96, 114, 118, 130, 132, 138 unsupervised dosing, 24, 32, 61 urine drug screening, 36, 160 'dipstick' methods, 36 directly observed, 37 limitations, 36, 46, 205 uses, 10, 36 vaccination, 52, 147 withdrawal, 32 assessment, 18, 191 precipitated by antagonists, 46, 47, 115, 116, 201 precipitated by buprenorphine, 21, 25, 27, 29, 34, 79, 99, 103 protracted, 84 signs and symptoms, 83, 88, 111, 134, 203
endorsed%20MATOD%20guidelines%20accessible%20Apr2014%20(D14-1005149).DOCX